Dirt Cheap Stocks to Buy With $1,000 Right Now

The article highlights three consumer stocks the author views as attractively valued: e.l.f. Beauty at 15x 2026 forward P/E, Chewy at under 14x, and JAKKS Pacific at 10x 2026 and under 7x 2027 estimates. Key catalysts include Rhode expansion for e.l.f., Chewy's path to 10% adjusted EBITDA margins from 5.7% last year with margins up 90 bps in 2025 and expected to rise another 100 bps this year, and JAKKS' planned anime/manga platform launching next year. Overall tone is bullish on valuation and operating leverage rather than on near-term macro conditions.

Analysis

The common thread is not “cheap consumer names” but asymmetric operating leverage where the market is still pricing these businesses as stagnant cyclicals. ELF’s real optionality is that Rhode can re-rate the whole platform from a mass-beauty multiple to a brand-portfolio multiple; if Sephora distribution broadens without requiring a step-up in spend, the incremental gross profit should drop through at an unusually high rate because the brand is already culturally seeded. The second-order winner is the retailer/distributor ecosystem that can monetize prestige traffic without carrying the brand-building risk.

CHWY looks like a classic “hidden software” story embedded in retail economics: the more wallets, autoship cadence, and service attach rates improve, the more fixed-cost dilution matters. The market is underestimating how much of the margin roadmap is self-funding rather than promotional; if fulfillment automation and mix shift both keep working, 100bps annual EBITDA expansion can persist longer than consensus expects, and the stock can re-rate before revenue growth re-accelerates. Key risk is not demand but reinvestment discipline—if management chases growth too aggressively in pharmacy or vet, the margin narrative loses credibility.

JAKK is the most mispriced because the catalyst window is longer-dated but the embedded optionality is very real. The market is valuing it as a low-quality licensed toy company, yet the anime/manga platform could create a higher-ASP, higher-margin product flywheel with international distribution potential; that matters because adult-leaning fandom categories often have better repeat purchase behavior and less seasonality than kids’ toys. The near-term setup is movie-slate driven, but the bigger move comes if management proves it can convert IP partnerships into a scalable platform rather than a one-off licensing experiment.

The consensus is underappreciating duration: these are not one-quarter stories. ELF and CHWY can work over the next 6-12 months through margin revision alone, while JAKK is a 12-24 month catalyst story with much higher variance. The main macro risk is a consumer spending air pocket or tariff-driven margin pressure, but these names are relatively insulated if their mix shift and gross margin expansion continue; the better risk/reward is owning the operating leverage before the estimates catch up.

Key Decisions for Investors

• Long ELF for 6-12 months into Rhode distribution expansion; size for rerating risk, not just EPS growth. Best case is multiple expansion as investors price a multi-brand beauty platform; stop if Rhode sell-through decelerates or marketing intensity spikes materially.
• Add to CHWY on weakness over the next 1-2 quarters; this is a margin-delta trade more than a top-line trade. Favor long-dated upside exposure if available, since the stock can re-rate before full EBITDA margin targets are reached.
• Initiate a small-cap catalyst long in JAKK for 12-24 months; high upside if anime platform becomes a credible new revenue engine, but expect volatility. Use position sizing that tolerates a failed launch without impairing the portfolio.
• Pair trade: long ELF / short a lower-quality discretionary name with weaker margin path, to isolate brand-led operating leverage versus pure consumer beta. The thesis is that balance-sheet and product mix improvements matter more than near-term category noise.
• If you want convexity, express CHWY via calls rather than stock into the next earnings cycle; the setup is for gradual margin surprise, and options let you capture a sharp rerating if EBITDA expansion outpaces guidance.